Abstract: Objective To explore the protective effects of geniposide on airway inflammation and smooth muscle cells (ASMCs) injury in infant asthma mice. Methods BALA/c mice were divided into three groups,including control group, asthmagroup, and geniposide group(80 mg/kg) (10 in each group). The pathological changes in experimental lung tissues, including cells infiltrating, goblet mucus secretion were detected by H&E staining and AB-PAS staining.The number of inflammatory cells in bronchoalveolar lavage fluid (BALF), including Eosinophils, Neutrophils, and Macrophages, was also observed.The levels of TLR4 and Th2 type cytokines IL-4, IL-5 and IL-13 in the BALF were determined by ELISA assay. Then, ASMCs were isolated and cultured in vitro. Cultured cells were divided into five groups, control group, asthma group (Ova), low dose of geniposide group(20mg/L), medium dose of geniposide group (50mg/L) and high dose of geniposide group (100mg/L)(8 in each group). The expression of TLR4 and NF-κB p65 were detected by qRT-PCR and Western blot analyses.The cell proliferation ability of ASMCs was determined using the MTT assay. Results In vivo studies, the results indicated that geniposide induced the decrease of asthma lung cells infiltrating and goblet mucus cells secretion, and the increase of inflammation cells（P<0.01），as well as the reduction of TLR4 and Th2 type cytokines secretion（P<0.01）.In vitro studies, the results demonstrated that geniposide inhibited TLR4/NF-κB activation, and restrained cell proliferation in asthma-derived ASMCs. Conclusions The effect of Geniposide reduces airway inflammation and ASMCs injury in infant asthma mice, which may be through the ability of inhibiting the TLR4/NF-κB activation.